Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for
minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic
hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing
the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem
cell transplantation (allo-HSCT).